Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
In a deal-making spree, Genentech will team up with the small companies to take on various diseases, including multiple sclerosis.
Blocking IL-6 pathway may extend duration of immunotherapy and reduce side effects
The companies indicate they hope to continue data analysis to better understand the disease and will present anything relevant at a future scientific meeting.
Research Team Combines Multi-Spectral Imaging and Supercomputing
Florida-based Hesperos is changing the paradigm of clinical development with its organ-on-a-chip technology and new research that demonstrates the platform can predict in vivo response to medications and reduce the need for animal testing.
Medical Research Council (MRC) Grants Funding for Bermekimab as Part of its Support for “Outstanding Clinical Programs in the United Kingdom”
Primary endpoint of event free survival (EFS) rate at 180 days of 90.9 percent reported for rivo‑cel in BP-004 European registrational trial
Immatics Biotechnologies GmbH announced that Harpreet Singh has been appointed the Company’s Chief Executive Officer.
Median progression-free survival for patients receiving Braftovi Triplet was 4.3 months compared to 1.5 months.
Process Could Be Similar to How First Living Cells Formed; Applications to Industry Possible